Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic Supplementation Safety and Feasibility Study in Preclinical Alzheimer's Disease
NCT07413744Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 1, randomised trial of probiotic oral spray in Alzheimer's disease (AD) (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Proportion of participants with an adverse event at 36 weeks, Proportion of participants with a severe adverse event at 36 weeks and 4 more. Started Nov 2026; status: recruiting.
02
Drugs
probiotic oral spray
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07413744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413744.